Clinical Trial Update: Patient-Reported Outcomes in Evaluating Lorecivivint (SM04690) for Moderate to Severe Knee Osteoarthritis (STRIDES-1) [Phase 3]

View source ↗

Summary

Phase 3 STRIDES-1 trial evaluating Lorecivivint (SM04690) for moderate-to-severe knee osteoarthritis has completed with results focusing on patient-reported out…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Knee Osteoarthritis

Drugs mentioned

• Lorecivivint (SM04690)

Snippet

Sponsor: Biosplice Therapeutics, Inc. | Conditions: Knee Osteoarthritis | Phase 3 | Status: COMPLETED | Results posted: 2026-02-04